Marjorie Taylor Greene
Trade Performance Intelligence
Score: 3/10Performance calculated from trade date to most recent market close. Real-time stock data from Financial Modeling Prep. This is not financial advice.
Stock Price at Trade vs. Today
Real market data showing how each stock moved since the congress member traded it.
Suspicious Timing Detected
3 flagsRep. Marjorie Taylor Greene bought $1,001 - $15,000 in $GILD on June 6, 2025 — 90 days before HR5127 ("PrEP and PEP are Prevention Act") was introduced, a bill that could increase demand for HIV prevention drugs.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | Government Securities | US Treasury Bill(Government Securities) | $100K-$250K | — | — | — | Jun 12, 2025 |
| BUY | $ADBE | Adobe Inc. - Common Stock | $1K-$15K | — | — | — | Jun 6, 2025 |
| BUY | $AMAT | Applied Materials, Inc. - Common Stock | $1K-$15K | — | — | — | Jun 6, 2025 |
| BUY | $GILD | Gilead Sciences, Inc. - Common Stock | $1K-$15K | — | — | — | Jun 6, 2025 |
| BUY | $NFLX | Netflix, Inc. - Common Stock | $1K-$15K | — | — | — | Jun 6, 2025 |
| BUY | $NEE | NextEra Energy, Inc. Common Stock | $1K-$15K | — | — | — | Jun 6, 2025 |
| BUY | $NOW | ServiceNow, Inc. Common Stock | $1K-$15K | — | — | — | Jun 6, 2025 |
| BUY | $SNOW | Snowflake Inc. Class A Common Stock | $1K-$15K | — | — | — | Jun 6, 2025 |
Connected Legislative Activity
7 signalsThese bills and contracts share tickers or sectors with this filing's trades.
PrEP and PEP are Prevention Act
The PrEP and PEP are Prevention Act mandates no-cost coverage for HIV prevention drugs and related services, directly increasing demand for these medications and associated diagnostic tests. This legislation creates a guaranteed market expansion for pharmaceutical companies producing PrEP/PEP drugs and diagnostic providers, while increasing costs for health insurers.
Strengthening Agency Management and Oversight of Software Assets Act
The 'Strengthening Agency Management and Oversight of Software Assets Act' (HR2417) mandates comprehensive software assessments and management plans for federal agencies, increasing demand for enterprise software and IT services. This bill is in the early stages, having been referred to committee on March 27, 2025. No direct appropriations are tied to this bill; funding will come from existing agency budgets.
Lowering Broadband Costs for Consumers Act of 2025
The 'Lowering Broadband Costs for Consumers Act of 2025' (HR4032) mandates increased Universal Service Fund contributions from broadband and 'edge providers,' directly raising operating costs for major internet service providers and large technology companies. This will reduce profit margins for affected companies. The bill is in the early stages, having been referred to committee, but has a companion bill (S1651) and 23 cosponsors, indicating moderate legislative momentum.
Small Biotech Innovation Act
The Small Biotech Innovation Act (HR3731) is in an early legislative stage, aiming to exempt research and development-intensive small biotech manufacturers from Medicare drug price negotiations. While the bill could protect future revenue streams for qualifying small biotech firms, there is no direct market reaction evident in the provided stock data for either large or small biotech firms.
Providing Veterans Essential Medications Act
The Providing Veterans Essential Medications Act, HR1970, aims to shift the financial burden of high-cost veteran medications to the VA, guaranteeing federal reimbursement for drug suppliers. This bill, currently in the early stages of the legislative process, would increase demand and payment certainty for pharmaceutical manufacturers and distributors within the VA system. The market has shown mixed reactions across pharmaceutical and healthcare distribution companies in the past 30 days, with some experiencing gains and others declines.
BRAIN Act
The BRAIN Act (HR2767) was introduced in the House and referred to committee, aiming to increase research and awareness for brain tumor treatment. This legislation, if passed, would create new grant opportunities and research networks, directly benefiting oncology and neuroscience-focused pharmaceutical, biotech, diagnostic, and life science tool companies. The bill is in an early stage but has a companion bill (S1330) in the Senate, indicating bipartisan and bicameral support.
Content Origin Protection and Integrity from Edited and Deepfaked Media Act of 2025
The Content Origin Protection and Integrity from Edited and Deepfaked Media Act of 2025 (S1396) mandates content provenance for AI-generated content, increasing operational costs and regulatory burdens for AI developers and large digital platforms. This bill is in the early stage, having been referred to the Committee on Commerce, Science, and Transportation on April 9, 2025. Companies like Alphabet, Meta Platforms, Microsoft, Amazon, NVIDIA, and Adobe face increased compliance costs if this legislation advances.
Live Charts
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.